The effect of parenteral pentoxifylline therapy on skin flap survival

Topalan, Murat; Arıncı, Atilla; Erer, Metin; Güvenç, Hüseyin

doi:10.1007/bf00192704

Cited by 7 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the last blood flow recording, flaps were removed by cutting the margin and animals sacrificed by a lethal dose of pentobarbital. Flap and necrotic areas were traced onto the same transparent plastic sheet and planimetrically measured in blind (SigmaScan Pro5 Images Measurement Software), as reported[ 34 ]. The necrotic area in the distal portion of the skin flap was easily demarcated by gross observation [ 30 ].…”

Section: Methodsmentioning

confidence: 99%

Propionyl-L-Carnitine Enhances Wound Healing and Counteracts Microvascular Endothelial Cell Dysfunction

et al. 2015

View full text Add to dashboard Cite

BackgroundImpaired wound healing represents a high cost for health care systems. Endothelial dysfunction characterizes dermal microangiopathy and contributes to delayed wound healing and chronic ulcers. Endothelial dysfunction impairs cutaneous microvascular blood flow by inducing an imbalance between vasorelaxation and vasoconstriction as a consequence of reduced nitric oxide (NO) production and the increase of oxidative stress and inflammation. Propionyl-L-carnitine (PLC) is a natural derivative of carnitine that has been reported to ameliorate post-ischemic blood flow recovery.Methods and ResultsWe investigated the effects of PLC in rat skin flap and cutaneous wound healing. A daily oral PLC treatment improved skin flap viability and associated with reactive oxygen species (ROS) reduction, inducible nitric oxide synthase (iNOS) and NO up-regulation, accelerated wound healing and increased capillary density, likely favoring dermal angiogenesis by up-regulation for iNOS, vascular endothelial growth factor (VEGF), placental growth factor (PlGF) and reduction of NADPH-oxidase 4 (Nox4) expression. In serum-deprived human dermal microvascular endothelial cell cultures, PLC ameliorated endothelial dysfunction by increasing iNOS, PlGF, VEGF receptors 1 and 2 expression and NO level. In addition, PLC counteracted serum deprivation-induced impairment of mitochondrial β-oxidation, Nox4 and cellular adhesion molecule (CAM) expression, ROS generation and leukocyte adhesion. Moreover, dermal microvascular endothelial cell dysfunction was prevented by Nox4 inhibition. Interestingly, inhibition of β-oxidation counteracted the beneficial effects of PLC on oxidative stress and endothelial dysfunction.ConclusionPLC treatment improved rat skin flap viability, accelerated wound healing and dermal angiogenesis. The beneficial effects of PLC likely derived from improvement of mitochondrial β-oxidation and reduction of Nox4-mediated oxidative stress and endothelial dysfunction. Antioxidant therapy and pharmacological targeting of endothelial dysfunction may represent a promising tool for the treatment of delayed wound healing or chronic ulcers.

show abstract

Section: Methodsmentioning

confidence: 99%

Propionyl-L-Carnitine Enhances Wound Healing and Counteracts Microvascular Endothelial Cell Dysfunction

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Other 8,9,11,13,14,[16][17][18][19][28][29][30][31][32] have demonstrated that parenteral administration of pentoxifylline with different schemes and doses ranging from 1 to 50 mg/kg, was able to improve tissue vitality.…”

Section: Discussionmentioning

confidence: 99%

“…It plays a role in morphological immunomodulation, decreases the inflammatory action, and has a fibrinogenic action, with decreased collagen synthesis. This potent antioxidant acts by inhibiting the superoxide anion synthesis and may reduce the toxic reperfusion metabolites, with a reduction in those responsible for tissue damage and consequent increase in flap survival 8,9,[11][12][13][14][15][16][17][18] .…”

Section: Introductionmentioning

confidence: 99%

Benefits of pentoxifylline for skin flap tissue repair in rats

et al. 2020

View full text Add to dashboard Cite

“…23 To salvage the failing¯aps, two general approaches were used. The ®rst approach was to increase blood¯ow, and the second to increase tolerance to ischemia.…”

Section: Discussionmentioning

confidence: 99%

Effects of some pharmacological agents on the survival of unipedicled venous flaps: an experimental study

et al. 2001

View full text Add to dashboard Cite

Clinical and experimental studies have been conducted to improve the survival of venous flaps. As a result of these studies, although various survival mechanisms were raised, none obtained satisfactory information. Venous stasis, and the resultant venous thrombosis, is a factor that decreases the survival of venous flaps. In this study, we evaluated the effects of two antiinflammatory agents, etodolac and etofenamate, on the survival of unipedicled venous flaps. In this study, 35 male New Zealand white rabbits (3,500-4,000 g) (70 ears) were used. Perichondrocutaneous flaps, 3 x 4.5 cm in size, were designed and raised, keeping the central veins intact in the middle of venous flap. Central arteries and nerves were ligated and transected both proximally and distally, to prepare unipedicled venous flaps. A silicone sheet was placed between the cartilage tissue and flap, to prevent blood flow and revascularization beneath. The subjects were divided into seven groups, consisting of five rabbits (10 ears). In the negative control group (group I), the single vascular pedicle of venous flaps, central veins were ligated and flaps sutured into their own place as the composite graft. In the positive control group (group II), after venous flaps were prepared, normal saline, 0.2 mL, was given subcutaneously. In the first of five experimental groups (group III), unfractionated heparin (100 U/day) was given subcutaneously. In the second experimental group (group IV), etodolac (5 mg/kg/day) was given subcutaneously. In the third experimental group (group V), etophenamate (5 mg/kg/day) was given orally through a feeding tube. In the fourth experimental group (group VI), parnaparin (5 anti-Xa U/kg/day) was given subcutaneously. In the fifth experimental group (group VII), nadroparin (5 anti-Xa U/kg/day) was given subcutaneously, about 7 days postoperatively. At the eighth postoperative day, surviving areas of venous flaps were measured, and the results were evaluated by Kruskal-Wallis ANOVA and Mann-Whitney U-test (P < 0.05). Biopsies were also taken from the flaps for histological evaluation of border of necrotic tissue. Surviving areas of unipedicled venous flaps were larger in experimental groups than those in negative and positive control group (P < 0.05). However, comparison of the experimental groups demonstrated no statistically significant difference (P > 0.05). We concluded that all pharmacological agents used in the experimental groups succeeded in increasing the survival of unipedicled venous flaps. Survival of the unipedicled venous flap was higher in venous flaps than that of composite graft, clearly showing the importance of the venous pedicle.

show abstract

The effect of parenteral pentoxifylline therapy on skin flap survival

Cited by 7 publications

References 8 publications

Propionyl-L-Carnitine Enhances Wound Healing and Counteracts Microvascular Endothelial Cell Dysfunction

Propionyl-L-Carnitine Enhances Wound Healing and Counteracts Microvascular Endothelial Cell Dysfunction

Benefits of pentoxifylline for skin flap tissue repair in rats

Effects of some pharmacological agents on the survival of unipedicled venous flaps: an experimental study

Contact Info

Product

Resources

About